Sygehus Lillebaelt Vejle Sygehus — Clinical Trial Site

41 Registered trials

11 Currently recruiting

Organisation

Sygehus Lillebaelt Vejle Sygehus

Location

Vejle, Denmark

Identifier

ORG-100031262

Address

Kabbeltoft 25, 7100, Denmark

Departments

4003:Onkologisk afdeling/KFE
Department of Anesthesiolgy
Department of Cardiology 76362000
Department of Hematology
Department of Medicine
Department of Medicine, Hematological Section
Department of Oncology
Department of Regional Health Research
Department of Respiratory Diseases
Dept. Of Hematology Section of Internal Medicine
Hematology
internal medicin
Lungemedicinsk Afdeling
Medical
Medical Department
N/A
Oncology
Onkologisk Afdeling
Onkologisk Afdelning
Orthopaedic Surgery

Clinical trials at this site (41)

Search interface

A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethas… Ended

2023-503444-13-00 Relapsed/refractory multiple myeloma 5 2023-03-29
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive… Ended

2023-503568-18-00 Early human epidermal growth factor receptor 2 (HER2) p 5 2021-04-13
A study of patients with colorectal cancer that have a genetic abnormality in the BRAF gene taking encorafenib plus cetuximab with or withou… Ended

2023-509405-77-00 Colorectal cancer (BRAF V600E-mutant mCRC) 5 2021-02-16
A Phase 3 Trial of Epcoritamab vs Investigator’s Choice Chemotherapy in R/R DLBCL Ended

2023-504830-23-00 B-cell Lymphoma 5 2020-12-16
Safety and Efficacy Study of Epcoritamab in Subjects with Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome Ended

2023-504828-25-00 Chronic Lymphocytic Leukemia 9 2020-11-16
Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) Ended

2023-504805-35-00 Lymphoma of B-cell origin 9 2020-10-22
A Phase 3 Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment … Ended

2023-506365-64-00 Deleterious Germline or Somatic Homologous Recombinatio 5 2020-10-16
POLAR BEAR Ended

2022-502887-19-00 Diffuse Large B-Cell Lymphoma 5 2020-08-18
A translational RANDOMIZED phase III study exploring the effect of the addition of capecitabine to Carboplatinum based chemotherapy in early… Ended

2022-501102-35-00 Early triple negative breast cancer 5 2019-12-02
A Phase 3, Multicenter, Randomized, Open Label Study of Venetoclax and Dexamethasone Compared with Pomalidomide and Dexamethasone in Subject… Ended

2023-506112-40-00 R/R Multiple Myeloma 5 2018-09-26
A Study of Tobemstomig/RO7247669 Combined with Nab-Paclitaxel Compared with Pembrolizumab Combined with Nab-Paclitaxel in Participants with … Ended

2022-502457-34-00 Triple-Negative Breast Cancer (TNBC) 4 2024-03-13
Clinical trial on Spinal Anaesthesia vs. General Anaesthesia (SAGA) on recovery after hip and knee replacements Ended

2022-501221-21-00 Osteoarthritis of the hip and knee 6 2023-02-03
A study to evaluate the effects of ALIS based treatment in patients newly diagnosed with nontuberculous mycobacterial lung infection caused … Ended

2023-505273-33-00 "Adult Subjects with Newly Diagnosed Nontuberculous Myc 5 2021-02-15
A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inop… Ended

2024-512331-72-00 Squamous Carcinoma of the Anal Canal 5 2020-12-22
Nivo versus Nivo/Ipi or versus other chemotherapies to treat colorectal cancer Ended

2023-503956-29-00 Microsatellite Instability High (MSI-H) or Mismatch Rep 5 2019-08-26
Danish trial of beta blocker treatment after myocardial infarction without reduced ejection fraction (DANBLOCK) Ended

2024-515748-22-01 Myocardinal infarction 5 2018-12-01
Study assessing the efficacy and safety of alpelisib plus fulvestrant or letrozole, based on prior endocrine therapy, in patients with PIK3C… Ended

2023-509167-24-00 Adult patients with PIK3CA mutant, HR-positive, HER2-ne 4 2017-10-02